RxDoctor Payments Data

Robert Otto, MD

Orthopaedic Surgery · Nashville, TNNPI 1003013947

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $55,299 of the $76,612 with a category attached, or 72.2%. Exactech, Inc. accounts for 84.1% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $32,471 and has fallen 98.7% since, to $438 in 2025.

$76,612in general payments, 2019–2025

Across 152 payments — averaging $504.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exactech, Inc.$64K
  • Medical Device Business Services, Inc.$9K
  • Johnson & Johnson$928
  • Stryker$588
  • Ferring Pharmaceuticals Inc.$481
  • Smith+Nephew$262
  • plus $1K from 14 others
$76,092in research payments, 2019–2025

Across 3 payments — averaging $25,364 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Exactech, Inc.$76K

What the payments were for

  • Consulting fees$55,29972%
  • Travel & lodging$6,9469%
  • Food & beverage$14,36719%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$76,612 in reported general payments places this provider in the 85th percentile of 381 orthopaedic surgery providers in Tennessee.

See all orthopaedic surgery providers in Tennessee

Medicare billing

Part B allowed, 2024
$255,371
Medicare patients
312
Services billed
3,250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban15$9,250
Oxycodone Hcl85$691
Cephalexin43$429
Ondansetron Hcl33$342
Pantoprazole Sodium58$325
Celecoxib19$286
Amoxicillin229$265
Meloxicam102$260
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$171
Diclofenac Sodium12$171
Ondansetron OdtOndansetron21$151
Hydromorphone Hcl14$132
Doxycycline Hyclate14$120
Mupirocin19$97
Dexamethasone41$68

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$928$9,25015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 381 orthopaedic surgery providers in Tennessee.

Other orthopaedic surgery in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →